Investor Presentation Q1 2023

23 Investor presentation First three months of 2023 Novo NordiskⓇ Novo Nordisk holds solid patent protection, high barriers to entry, and a collaborative approach to innovation Novo Nordisk's position is protected by patents and value chain setup OZEMPIC semaglutide injection RYBELSUS® semaglutide tablets Fiasp® fast-acting insulin aspart esperoct turoctocog alfa pegol Xultophy insulin degludec/liraglutide [rDNA origin] injection EU/US patent protection1 2031/322 2031/20322,3 20304 2034/322 • 2028/29 • TRESIBA 2028/29 insulin degludec [rDNA origin] injection RYZODEG 70% insulindegudec and 30% insulin aspart [rDNA origin injection refixia® 2028/29 2027/28 Barriers to entry for biosimilar players Research & Development Need to show comparability in PK/PD trials Strict regulatory requirements in the EU and the US Requirement for both drug and device offering Manufacturing Economies of scale Up-front CAPEX requirements with slow return on investment Commercialisation Large and fragmented target audience Cost pressure from payers On-going conversion to next-generation drugs and slow market dynamics Partnerships and acquisitions support future R&D siRNA treatments Dicerna™ Oral formulations of therapeutics Combination treatments for NASH GILEAD Gene editing for haemophilia Emisphere seventybio! Novel treatments for CVD/Rare disease of prothena VICTOZAⓇ liraglutide injection 20235 CORVIDIA Precision Cardiovascular Therapeutic Heartseed forma THERAPEUTICS. 1 List does not include all marketed products. 2 Current estimates. WegovyⓇ patent identical to OzempicⓇ patent; 3 Tablet formulation and once-daily treatment regimen are protected by additional patents expiring in 2031-2034; 4 Formulation patent; active ingredient patent has expired; 5 SaxendaⓇ patent identical to VictozaⓇ patent. PK: Pharmacokinetic, PD: Pharmacodynamic; CAPEX: Capital expenditure; siRNA: Silencing ribonucleic acid; NASH: Non-alcoholic steatohepatitis; CVD: Cardiovascular disease

View entire presentation